Non-hydrolysable analogs of retinal chromophore; potential new therapeutics to prevent retinal degeneration

视网膜发色团的不可水解类似物;

基本信息

  • 批准号:
    9899990
  • 负责人:
  • 金额:
    $ 35.66万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2016
  • 资助国家:
    美国
  • 起止时间:
    2016-04-01 至 2021-03-31
  • 项目状态:
    已结题

项目摘要

 DESCRIPTION (provided by applicant): An insufficient supply of visual chromophore due to dysfunction of key proteins involved in its regeneration has devastating effects on rod-mediated vision, and comprises a leading cause of irreversible blindness in humans. Early signs of such blinding diseases are delayed rod cell-mediated dark adaptation and difficulty with night vision. The decline in recovery of visual sensitivity is likely caused by inadequate Rho regeneration with accumulation of chromophore-free opsin that constitutively activates the signaling cascade and accelerates retinal degeneration. Although such free opsin activity can be reduced by exogenous retinal chromophore, this fails to prevent the buildup of toxic retinoid photo-products when their clearance is defective. Thus, an alternative therapeutic approach is urgently needed for combating vision loss under such conditions. Here we propose to investigate the effects of new visual pigments, retinyl-opsins regenerated with novel chromophore analogs, retinyl chlorides on retina physiology in context of potential therapeutic strategy to protect retinal healh in retinal degenerative diseases associated with compromised Rho regeneration. First, we will study the biochemical and functional properties of different retinyl chloride isomers in vitro (Aim 1), and then test the effects of selected retinyl chlorides in both Abca4-/-Rdh8-/- mice, a model of early onset human Stargardt disease and in Lrat-/- mice, a model of Leber congenital amaurosis (LCA) (Aim 2). Finally, we will assess the capability of the RBP4 carrier to increase the ocular delivery of these compounds, and thereby alleviate progressive retinal degeneration in these mouse models (Aim 3).
 描述(由申请人提供):由于参与其再生的关键蛋白质功能障碍,视觉生色团的供应不足,对视杆介导的视力具有毁灭性的影响,并构成人类不可逆性失明的主要原因。这种致盲疾病的早期症状是视杆细胞介导的暗适应延迟和夜视困难。视觉敏感度恢复的下降可能是由于Rho再生不足,无生色团的视蛋白积累,结构性地激活了信号级联,加速了视网膜的退化。虽然这种游离视蛋白活性可以通过外源性视网膜发色团减少,但这不能防止有毒的类维A酸类光产物的积累,因为它们的清除是有缺陷的。因此,迫切需要一种替代的治疗方法来对抗这种情况下的视力丧失。在这里,我们建议在潜在的治疗策略的背景下,研究新的视觉色素、用新的发色团类似物再生的视黄酰视蛋白、视黄醇氯化物对视网膜生理学的影响,以保护与Rho再生受损相关的视网膜退行性疾病的视网膜健康。首先,我们将在体外研究不同的视黄酰氯异构体的生化和功能性质(目的 1),然后在ABCA4-/-Rdh8-/-小鼠(早发性人类Stargardt病模型)和Lrat-/-小鼠(Leber先天性黑色素(LCA)模型)上测试选定的视黄酰氯的效果(目标2)。最后,我们将评估RBP4载体增加这些化合物的眼部递送的能力,从而缓解这些小鼠模型中的进行性视网膜退化(目标3)。

项目成果

期刊论文数量(3)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Beata Jastrzebska其他文献

Beata Jastrzebska的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Beata Jastrzebska', 18)}}的其他基金

Novel neuroprotective activities of flavonoids against retinal degenerative diseases
黄酮类化合物对视网膜退行性疾病的新型神经保护活性
  • 批准号:
    10704506
  • 财政年份:
    2022
  • 资助金额:
    $ 35.66万
  • 项目类别:
Novel neuroprotective activities of flavonoids against retinal degenerative diseases
黄酮类化合物对视网膜退行性疾病的新型神经保护活性
  • 批准号:
    10428740
  • 财政年份:
    2022
  • 资助金额:
    $ 35.66万
  • 项目类别:
Non-hydrolysable analogs of retinal chromophore; potential new therapeutics to prevent retinal degeneration
视网膜发色团的不可水解类似物;
  • 批准号:
    9026350
  • 财政年份:
    2016
  • 资助金额:
    $ 35.66万
  • 项目类别:

相似海外基金

I(eye)-SCREEN: A real-world AI-based infrastructure for screening and prediction of progression in age-related macular degeneration (AMD) providing accessible shared care
I(eye)-SCREEN:基于人工智能的现实基础设施,用于筛查和预测年龄相关性黄斑变性 (AMD) 的进展,提供可及的共享护理
  • 批准号:
    10102692
  • 财政年份:
    2024
  • 资助金额:
    $ 35.66万
  • 项目类别:
    EU-Funded
Inhibiting Neovascularization and Subretinal Fibrosis in Neovascular Age-Related Macular Degeneration
抑制新生血管性年龄相关性黄斑变性的新生血管形成和视网膜下纤维化
  • 批准号:
    10639785
  • 财政年份:
    2023
  • 资助金额:
    $ 35.66万
  • 项目类别:
Inhibition of melanogenesis in retinal pigment epithelium, a contributing factor in age-related macular degeneration
抑制视网膜色素上皮中的黑色素生成,这是年龄相关性黄斑变性的一个促成因素
  • 批准号:
    23K09052
  • 财政年份:
    2023
  • 资助金额:
    $ 35.66万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Deciphering the role of osteopontin in the aging eye and age-related macular degeneration
破译骨桥蛋白在眼睛老化和年龄相关性黄斑变性中的作用
  • 批准号:
    10679287
  • 财政年份:
    2023
  • 资助金额:
    $ 35.66万
  • 项目类别:
Evaluation of New Anti-inflammatory Treatments for Age-Related Macular Degeneration
年龄相关性黄斑变性的新型抗炎治疗方法的评价
  • 批准号:
    10642988
  • 财政年份:
    2023
  • 资助金额:
    $ 35.66万
  • 项目类别:
Progression of Early Atrophic Lesions in Age-related Macular degeneration
年龄相关性黄斑变性早期萎缩性病变的进展
  • 批准号:
    10635325
  • 财政年份:
    2023
  • 资助金额:
    $ 35.66万
  • 项目类别:
Cellular and molecular mechanisms of AIM2 and NLRP3 inflammasome activation in age-related macular degeneration
年龄相关性黄斑变性中 AIM2 和 NLRP3 炎症小体激活的细胞和分子机制
  • 批准号:
    10584110
  • 财政年份:
    2023
  • 资助金额:
    $ 35.66万
  • 项目类别:
Elucidation of roles of mast cells and macrophages in the pathogenesis of age-related macular degeneration
阐明肥大细胞和巨噬细胞在年龄相关性黄斑变性发病机制中的作用
  • 批准号:
    22H03243
  • 财政年份:
    2022
  • 资助金额:
    $ 35.66万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
AMD Mitochondria Modulate Expression of microRNA 135b-5p and 148a-3p in RPE Cybrids: Implications for Age-related Macular Degeneration
AMD 线粒体调节 RPE Cybrids 中 microRNA 135b-5p 和 148a-3p 的表达:对年龄相关性黄斑变性的影响
  • 批准号:
    10433610
  • 财政年份:
    2022
  • 资助金额:
    $ 35.66万
  • 项目类别:
Targeting the inflammatory response in age-related macular degeneration
针对年龄相关性黄斑变性的炎症反应
  • 批准号:
    10504138
  • 财政年份:
    2022
  • 资助金额:
    $ 35.66万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了